Franklin Berger

Franklin Berger has served as a member of Kezar Life Sciences Board of Directors since January 2016. Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from January 2007 through June 2008.

Prior to that, he served at J.P. Morgan Securities, most recently as the Managing Director, Equity Research and Senior Biotechnology Analyst and served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger has served as a member of the board of directors of Five Prime Therapeutics, Inc. since October 2014, Tocagen Inc since October 2014, Bellus Health, Inc. since May 2010, ESSA Pharma, Inc. since March 2015, and Proteostasis Therapeutics, Inc. since February 2016. Mr. Berger previously served as a member of the board of directors BioTime, Inc., Seattle Genetics, Inc., and Immune Design Corp, each publicly held biotechnology company.

Mr. Berger received a Bachelor of Arts in International Relations and an M.A. degree in International Economics from Johns Hopkins University, and an M.B.A. degree from the Harvard Business School.